An update on the management of SUI in women

Oral sulopenem demonstrates non-inferiority to amoxicillin/clavulanate in phase 3 uUTI trial

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Morgan Ebert, Managing Editor

Vaginal laser not found superior to sham for SUI treatment

Oral sulopenem (ORLYNVAH; Iterum Therapeutics) was non-inferior to amoxicillin/clavulanate for treating uUTIs in women, per the phase 3 REASSURE trial.

Tebipenem HBr cUTI trial ends early after meeting efficacy goals

A new randomized trial shows Er:YAG laser therapy offers no significant benefit over sham treatment for managing female stress urinary incontinence at 6 months.

Karyn S. Eilber, MD, discusses updates on management of genitourinary syndrome of menopause

GSK and Spero Therapeutics announced that the phase 3 PIVOT-PO trial for tebipenem HBr, a potential first oral carbapenem for cUTIs in the United States, was stopped early because of positive efficacy results.

Karyn S. Eilber, MD

No superiority for onabotulinumtoxinA vs sling for urinary incontinence

In this Q&A, Karyn S. Eilber, MD, shares some of the biggest takeaways from the new AUA/SUFU/AUGS 2025 Guidelines on Genitourinary Syndrome of Menopause.

Contemporary OB/GYN week in review: breast cancer prevention, uUTI trial, and more

A new study finds no significant difference in symptom improvement between onabotulinumtoxinA injections and midurethral sling surgery for women with mixed urinary incontinence.

Related Content

Oral sulopenem demonstrates non-inferiority to amoxicillin/clavulanate in phase 3 uUTI trial

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Morgan Ebert, Managing Editor

Vaginal laser not found superior to sham for SUI treatment

Oral sulopenem (ORLYNVAH; Iterum Therapeutics) was non-inferior to amoxicillin/clavulanate for treating uUTIs in women, per the phase 3 REASSURE trial.

Tebipenem HBr cUTI trial ends early after meeting efficacy goals

A new randomized trial shows Er:YAG laser therapy offers no significant benefit over sham treatment for managing female stress urinary incontinence at 6 months.

Karyn S. Eilber, MD, discusses updates on management of genitourinary syndrome of menopause

Karyn S. Eilber, MD

No superiority for onabotulinumtoxinA vs sling for urinary incontinence

In this Q&A, Karyn S. Eilber, MD, shares some of the biggest takeaways from the new AUA/SUFU/AUGS 2025 Guidelines on Genitourinary Syndrome of Menopause.